Latest news
Iconovo signs an agreement with Stevanato Group regarding the manufacture, sale and distribution of ICOcap
The inhalation developer Iconovo AB (publ) announced today that the company has signed an agreement with the multinational Stevanato Group, headquartered…
Dr Orest Lastow is lecturing at Dry Powder Inhalers Annual Conference London 20-21 June 2018
The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great…
Press releases
Jun 03, 2022, 15:57
News
IR
English
Corporate Information
Other Corporate Information
Jun 01, 2022, 07:52
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
May 23, 2022, 10:25
News
IR
Swedish
Corporate Information
Other Corporate Information
May 17, 2022, 13:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
May 02, 2022, 13:30
News
IR
English
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
Swedish
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
English
Corporate Information
Other Corporate Information
Apr 29, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
Apr 19, 2022, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 12, 2022, 08:45
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 29, 2022, 13:00
News
IR
English
Corporate Information
Other Corporate Information
Mar 25, 2022, 16:45
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Feb 21, 2022, 09:15
News
IR
English
Corporate Information
Other Corporate Information
Feb 18, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 09, 2022, 10:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 09, 2022, 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
